• Severely reduced cardiac output → hypotension and tissue hypoxia
• ↑ LV filling pressures → pulmonary congestion/edema
• Compensatory vasoconstriction → ↑ afterload, worsening cardiac output

Common Etiologies

• Acute myocardial infarction (most common; esp. large anterior MI)
• Severe acute decompensated heart failure
• Mechanical complications of MI (papillary muscle rupture, VSD)
• Malignant arrhythmias
• Acute myocarditis or cardiomyopathy
• Drug-induced myocardial depression (e.g., β-blockers, CCBs, antiarrhythmics)

Clinical & Hemodynamic Features

• Hypotension: SBP < 90 mmHg or MAP < 65 mmHg
• Low cardiac index: < 2.2 L/min/m²
• Elevated filling pressures (PCWP > 15 mmHg)
• Signs of hypoperfusion:
  • Altered mental status
  • Cold, clammy extremities
  • Oliguria
  • Elevated lactate

Pharmacist-Relevant Management Principles

• Immediate cause treatment (urgent revascularization if MI)
• Hemodynamic support:
  • Norepinephrine → first-line vasopressor
  • Dobutamine → inotrope for low cardiac output
• Avoid excess fluids (risk of pulmonary edema)
• Review and hold negative inotropes when appropriate
• Dose-adjust medications for renal/hepatic hypoperfusion
• Antithrombotic therapy often required (MI context)

Advanced Therapies (ICU/CCU)

• Mechanical circulatory support:
  • IABP, Impella, VA-ECMO
• Continuous hemodynamic monitoring

Key Pharmacist TakeawayCardiogenic shock is pump failure shock, not volume depletion—vasopressor–inotrope balance, medication optimization, and organ-based dose adjustment are central pharmacist responsibilities.If you’d like, I can also provide:

• • A one-page cardiogenic shock drug algorithm
  • Vasopressor/inotrope comparison table
  • Medication dosing pearls in shock states

Cardiogenic shock drug algorithm

It is guideline-aligned (AHA/ESC practice) and optimized for bedside use.

Pharmacologic Management Algorithm

1. Immediate Assessment (0–10 min) Confirm shock

• • • MAP < 65 mmHg or SBP < 90 mmHg
    • Signs of hypoperfusion (AMS, oliguria, lactate ↑)
    • Evidence of cardiac pump failure (echo, CI < 2.2)

Pharmacist actions

• • • Hold negative inotropes (β-blockers, non-DHP CCBs)
    • Review recent cardio depressant drugs (antiarrhythmics, sedatives)
    • Baseline labs: lactate, ABG, CMP, LFTs, troponin

2. Initial Hemodynamic Stabilization

First-Line Vasopressor
NOREPINEPHRINE

• • • Start: 0.05–0.3 mcg/kg/min
    • Target: MAP ≥ 65 mmHg
    • Rationale: Best survival signal, minimal ↑ HR

Avoid dopamine (↑ arrhythmias, mortality)

3. Assess Cardiac Output If MAP achieved but persistent hypoperfusion:

• • • Cold extremities
    • Low CI
    • Rising lactate

Add Inotrope DOBUTAMINE

• • • Start: 2–5 mcg/kg/min
    • Max: 20 mcg/kg/min
    • Monitor: HR, arrhythmias, hypotension

Alternative

• • • Milrinone (if on chronic β-blocker or RV failure)
      • Use cautiously (hypotension, renal clearance)

4. Blood Pressure Still Low?

If MAP < 65 despite NE ± dobutamine:

• • • Add vasopressin 0.03 units/min
    • Consider epinephrine (rescue only)

5. Volume Strategy

• • • Small test bolus (250 mL) only if hypovolemia suspected
    • Avoid routine fluids → pulmonary edema risk

6. Etiology-Directed Pharmacotherapy

AMI-related shock

• • • Dual antiplatelet therapy (if appropriate)
    • Anticoagulation
    • Urgent revascularization (definitive therapy)

Arrhythmia-induced shock

• • • Electrical cardioversion preferred
    • Avoid cardiodepressant antiarrhythmics when possible

Mechanical complications

• • • Stabilize → emergent surgery

7. Reassess Every 15–30 min

• • • MAP, HR, lactate
    • Urine output
    • Renal/hepatic function

Pharmacist duties

• • • Dose-adjust renally cleared drugs
    • Review antibiotics (AKI risk)
    • Avoid nephrotoxins

8. Escalation

If refractory shock:

• • • Mechanical circulatory support
      • IABP, Impella, VA-ECMO
    • Continue vasopressor/inotrope optimization

Quick Drug Pearls

• • • NE > dopamine for mortality benefit
    • Inotrope only after BP supported
    • Positive DAT or anemia? Re-evaluate hemolysis if transfusions given
    • Shock alters PK/PD → under- or over-dosing risk